GH Research (GHRS) investor relations material

Clinical highlights and efficacy

• GH001 demonstrated rapid and durable remission in treatment-resistant depression (TRD), with 57.5% remission at Day 8 and 73% at 6 months in open-label extension completers.

• The psychoactive phase of GH001 lasts approximately 11 minutes, enabling up to three treatments per clinic visit and reducing clinic time compared to alternatives.

• GH001 showed consistent efficacy across all levels of prior treatment failures, unlike the progressive decline seen in standard therapies.

• Significant improvements were observed in depression, anxiety, anhedonia, and quality of life measures, with rapid onset and sustained benefit.

• GH001 was well-tolerated across TRD, postpartum depression, and bipolar II disorder, with mostly mild to moderate adverse events and no treatment-related serious adverse events.

Competitive positioning and operational advantages

• GH001 fits into existing Spravato-compatible clinic models, offering up to 83% fewer treatment visits over six months compared to Spravato.

• The product enables up to three treatments per visit, with most patients discharge-ready within one hour after the last dose.

• GH001’s short duration and flexible dosing provide a unique advantage over other psychedelics and rapid-acting antidepressants.

Pipeline and financials

• GH001 is advancing to Phase 3 for TRD, with completed Phase 2b and open-label extension studies.

• Additional indications in postpartum depression and bipolar II disorder are in earlier clinical stages.

• Cash, cash equivalents, and marketable securities totaled $362.7 million as of June 30, 2026, supporting ongoing and planned studies.